GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » ROE %

Sino Biopharmaceutical (FRA:SMZ1) ROE % : 7.09% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sino Biopharmaceutical's annualized net income for the quarter that ended in Dec. 2023 was €276 Mil. Sino Biopharmaceutical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was €3,889 Mil. Therefore, Sino Biopharmaceutical's annualized ROE % for the quarter that ended in Dec. 2023 was 7.09%.

The historical rank and industry rank for Sino Biopharmaceutical's ROE % or its related term are showing as below:

FRA:SMZ1' s ROE % Range Over the Past 10 Years
Min: 7.7   Med: 23.43   Max: 79.96
Current: 7.7

During the past 13 years, Sino Biopharmaceutical's highest ROE % was 79.96%. The lowest was 7.70%. And the median was 23.43%.

FRA:SMZ1's ROE % is ranked better than
88.31% of 1360 companies
in the Biotechnology industry
Industry Median: -44.355 vs FRA:SMZ1: 7.70

Sino Biopharmaceutical ROE % Historical Data

The historical data trend for Sino Biopharmaceutical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical ROE % Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.79 17.32 64.30 8.36 7.54

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.13 12.81 4.06 8.22 7.09

Competitive Comparison of Sino Biopharmaceutical's ROE %

For the Biotechnology subindustry, Sino Biopharmaceutical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's ROE % distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's ROE % falls into.



Sino Biopharmaceutical ROE % Calculation

Sino Biopharmaceutical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=299.486/( (4027.884+3913.768)/ 2 )
=299.486/3970.826
=7.54 %

Sino Biopharmaceutical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=275.646/( (3865.183+3913.768)/ 2 )
=275.646/3889.4755
=7.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Sino Biopharmaceutical  (FRA:SMZ1) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=275.646/3889.4755
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(275.646 / 2805.472)*(2805.472 / 8314.389)*(8314.389 / 3889.4755)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.83 %*0.3374*2.1377
=ROA %*Equity Multiplier
=3.32 %*2.1377
=7.09 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=275.646/3889.4755
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (275.646 / 561.42) * (561.42 / 616.348) * (616.348 / 2805.472) * (2805.472 / 8314.389) * (8314.389 / 3889.4755)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.491 * 0.9109 * 21.97 % * 0.3374 * 2.1377
=7.09 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sino Biopharmaceutical ROE % Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (FRA:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines